

IN THE UNITED STATES DISTRICT COURT  
FOR THE WESTERN DISTRICT OF LOUISIANA  
LAFAYETTE DIVISION

THE STATE OF LOUISIANA, *et al.*,

*Plaintiffs,*

v.

No. 6:25-cv-01491-DCJ-DJA

U.S. FOOD AND DRUG  
ADMINISTRATION, *et al.*,

*Defendants.*

DEFENDANTS' MOTION TO STAY THE CASE

Defendants respectfully move that this Court stay all proceedings in this matter pursuant to its inherent authority while the U.S. Food and Drug Administration reviews the mifepristone Risk Evaluation and Mitigation Strategy. The grounds for this motion are fully set forth in the accompanying memorandum of law. If the Court grants this motion, Defendants will file a status report within 14 days of any decision concerning whether modifications to the REMS are necessary.

January 27, 2026

Respectfully submitted,

BRETT A. SHUMATE  
Assistant Attorney General

JAMES W. HARLOW  
Acting Assistant Director

/s/ Noah T. Katzen  
NOAH T. KATZEN  
Trial Attorney  
Federal Programs Branch  
Civil Division

U.S. Department of Justice  
1100 L St., NW  
Washington, DC 20005  
202-305-2428  
Noah.T.Katzen@usdoj.gov

*Counsel for Defendants*

### CERTIFICATE OF CONFERENCE

I hereby certify that, pursuant to Local Rule 7.4.1, counsel conferred in good faith regarding the relief sought in this motion. Plaintiffs oppose this motion. One of the parties that has given notice of intent to intervene, Danco Laboratories, reports through counsel that “Danco will respond to the Federal Defendants’ motion to stay as part of its own forthcoming motion to intervene, after Danco has had an opportunity to review Federal Defendants’ filing.” The other party that has given notice of intent to intervene, GenBioPro, likewise has advised through counsel “that it will need to review the Government’s motion to determine what position, if any, it takes on the requested stay, and will address that issue in its upcoming motion to intervene.”

/s/ Noah T. Katzen  
Noah T. Katzen